Kristi Rosa

The FDA cleared therapeutic options in pNETs/epNETs, MIBC, and mCRPC; experts highlight top abstracts ahead of 2025 EBMT; and more from OncLive.

Fulzerasib plus cetuximab elicited deep efficacy in patients with KRAS G12C–mutated NSCLC enrolled in the phase 2 KROCUS study.

Adagrasib plus pembrolizumab continued to show promising efficacy in patients with KRAS G12C–mutated NSCLC and PD-L1 TPS of 50% or higher.

Amivantamab plus lazertinib provides long-term survival benefit over osimertinib in EGFR-mutated advanced non–small cell lung cancer.

The FDA has approved cabozantinib (Cabometyx) for use in select patients with pancreatic and extra-pancreatic neuroendocrine tumors.

The top 5 OncLive videos of the week cover insights in gynecologic cancer, multiple myeloma, urothelial cancer, MPNs, and prostate cancer.

Pembrolizumab combination gets full approval in select HER2+ gastric/GEJ cancer, PSMA PET imaging agent is cleared for prostate cancer, and more from OncLive.

The top 5 OncLive videos of the week cover insights in colorectal cancer, myeloma, HER2+ breast cancer, and KRAS G12X+ pancreatic ductal adenocarcinoma.

Mirvetuximab soravtansine continued to showcase superior OS, PFS, ORR, & DOR benefits over chemotherapy in FRα-positive platinum-resistant ovarian cancer.

Patritumab deruxtecan elicited responses with acceptable safety in hormone receptor–positive, HER2-negative advanced breast cancer.

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab provides meaningful OS benefits in high-risk, early-stage TNBC.

The FDA has approved tislelizumab-jsgr plus chemotherapy for frontline use in adult patients with advanced esophageal squamous cell carcinoma and PD-L1 expression.

Perioperative pembrolizumab sBLA gets priority review in HNSCC, nivolumab/ipilimumab sBLA in MSI-H/dMMR CRC is under review, and more from OncLive this week.

Here is your snapshot for all therapeutic options that were approved by the FDA in February 2025 spanning tumor types.

The top 5 videos of the week cover insights in prostate cancer, multiple myeloma, RCC, urothelial carcinoma, and LBCL.

FDA grants priority review to zongertinib in HER2-mutant NSCLC and dordaviprone for recurrent H3K27M+ diffuse glioma, and more from OncLive this week.

SIGX1094 received fast track designation from the FDA for diffuse gastric cancer.

Ide-cel proved feasible and effective in boosting response in patients with myeloma with suboptimal response to standard frontline therapy.

The top 5 videos of the week cover insights in plexiform neurofibromas, melanoma, myeloma, leukemia, and LBCL.

CBM588 plus cabozantinib and nivolumab shows early efficacy in metastatic renal cell carcinoma.

Enfortumab vedotin plus pembrolizumab maintains compelling benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.

Mirdametinib is approved in select plexiform neurofibromas, experts preview top ASCO GU abstracts, NCCN updates ctDNA stance in several tumors, and more.

Cilta-cel led to rapid and deep MRD negativity in patients with lenalidomide-refractory multiple myeloma.

Consistent DFS benefit was observed with adjuvant nivolumab vs placebo in all patients with muscle-invasive bladder cancer enrolled in CheckMate-274.

The designation underscores the potential of the CAR T-cell therapy NXC-201 to serve as a new option in relapsed/refractory AL amyloidosis.

Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.

The top 5 videos of the week cover insights in lung cancer, multiple myeloma, breast cancer, and follicular lymphoma.

Pembrolizumab warrants further evaluation in patients with previously treated advanced clear cell gynecologic cancer in a randomized clinical trial.

Encorafenib combination boosts survival in BRAF V600E+ mCRC, pertuzumab biosimilar BLA is under review for HER2+ breast cancer, and more from OncLive.

Here is your snapshot of all therapeutic options that were approved by the FDA in January 2025 spanning tumor types.